Login
MediWound Ltd. logo

MediWound Ltd.

mediwound.com

What Do They Do?

Sells NexoBrid, an enzyme-based treatment that removes dead tissue from severe burns, to burn centers and hospital burn units, and develops enzymatic treatments for chronic wounds and a topical treatment for basal cell carcinoma.

How Do They Make Money?

Sells NexoBrid to burn centers and hospital burn units, with product revenue generally tied to delivery. Licensing deals can bring upfront fees, milestone payments and royalties tied to sales; development services generate revenue over the period they are provided.

FY2025 revenue

Who Are Their Customers?

Burn centers and hospital burn units receive NexoBrid through the company’s commercial organizations and local distributors. The company has local distribution agreements across Europe, Asia-Pacific and the Middle East.

How Are They Changing?

Shrinking. Revenue fell 29% in 4 years, from $23.8M in FY2021 to $17M in FY2025, about 8% a year.

Who Do They Compete With?

Competes with Smith & Nephew

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support